Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment

医学 痛风 内科学 耐受性 耐火材料(行星科学) 不利影响 天体生物学 物理
作者
John S. Sundy,Herbert S. B. Baraf,Robert A. Yood,N. Lawrence Edwards,Sergio Gutiérrez‐Ureña,Edward L. Treadwell,Janitzia Vázquez-Mellado,William B. White,Peter E. Lipsky,Zeb Horowitz,William J. Huang,Allan N. Maroli,Royce W. Waltrip,Steven A. Hamburger,Michael A. Becker
出处
期刊:JAMA [American Medical Association]
卷期号:306 (7): 711-711 被引量:514
标识
DOI:10.1001/jama.2011.1169
摘要

Context

Patients with chronic disabling gout refractory to conventional urate-lowering therapy need timely treatment to control disease manifestations related to tissue urate crystal deposition. Pegloticase, monomethoxypoly(ethylene glycol)–conjugated mammalian recombinant uricase, was developed to fulfill this need.

Objective

To assess the efficacy and tolerability of pegloticase in managing refractory chronic gout.

Design, Setting, and Patients

Two replicate, randomized, double-blind, placebo-controlled trials (C0405 and C0406) were conducted between June 2006 and October 2007 at 56 rheumatology practices in the United States, Canada, and Mexico in patients with severe gout, allopurinol intolerance or refractoriness, and serum uric acid concentration of 8.0 mg/dL or greater. A total of 225 patients participated: 109 in trial C0405 and 116 in trial C0406.

Intervention

Twelve biweekly intravenous infusions containing either pegloticase 8 mg at each infusion (biweekly treatment group), pegloticase alternating with placebo at successive infusions (monthly treatment group), or placebo (placebo group).

Main Outcome Measure

Primary end point was plasma uric acid levels of less than 6.0 mg/dL in months 3 and 6.

Results

In trial C0405 the primary end point was reached in 20 of 43 patients in the biweekly group (47%; 95% CI, 31%-62%), 8 of 41 patients in the monthly group (20%; 95% CI, 9%-35%), and in 0 patients treated with placebo (0/20; 95% CI, 0%-17%; P < .001 and <.04 for comparisons between biweekly and monthly groups vs placebo, respectively). Among patients treated with pegloticase in trial C0406, 16 of 42 in the biweekly group (38%; 95% CI, 24%-54%) and 21 of 43 in the monthly group (49%; 95% CI, 33%-65%) achieved the primary end point; no placebo-treated patients reached the primary end point (0/23; 95% CI, 0%-15%; P = .001 and < .001, respectively). When data in the 2 trials were pooled, the primary end point was achieved in 36 of 85 patients in the biweekly group (42%; 95% CI, 32%-54%), 29 of 84 patients in the monthly group (35%; 95% CI, 24%-46%), and 0 of 43 patients in the placebo group (0%; 95% CI, 0%-8%; P < .001 for each comparison). Seven deaths (4 in patients receiving pegloticase and 3 in the placebo group) occurred between randomization and closure of the study database (February 15, 2008).

Conclusion

Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.

Trial Registration

clinicaltrials.gov Identifier: NCT00325195
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
上官若男的应助被jwin采纳,获得10
1秒前
Ffffa完成签到,获得积分20
2秒前
2秒前
酷波er的应助被zht采纳,获得10
4秒前
4秒前
被风吹过的路的应助被ke采纳,获得10
4秒前
共享精神的应助被yu采纳,获得10
4秒前
4秒前
在水一方的应助被科研通管家采纳,获得10
4秒前
大模型的应助被科研通管家采纳,获得10
4秒前
所所的应助被科研通管家采纳,获得10
4秒前
Owen的应助被科研通管家采纳,获得10
5秒前
大个的应助被科研通管家采纳,获得10
5秒前
LuXiaoyu的应助被念汐采纳,获得10
5秒前
Ava的应助被科研通管家采纳,获得10
5秒前
赘婿的应助被科研通管家采纳,获得10
5秒前
852的应助被Grace采纳,获得10
5秒前
所所的应助被科研通管家采纳,获得10
5秒前
思源的应助被科研通管家采纳,获得10
5秒前
俏皮的三毒完成签到 ,获得积分10
5秒前
5秒前
秋风的应助被科研通管家采纳,获得10
5秒前
桐桐的应助被科研通管家采纳,获得10
6秒前
852的应助被科研通管家采纳,获得30
6秒前
李爱国的应助被科研通管家采纳,获得10
6秒前
6秒前
传奇3的应助被科研通管家采纳,获得10
6秒前
6秒前
molihuakai的应助被科研通管家采纳,获得10
6秒前
6秒前
聪明的巧荷完成签到,获得积分10
7秒前
科目三的应助被科研通管家采纳,获得10
7秒前
Owen的应助被科研通管家采纳,获得10
7秒前
啊熙发布了新的文献求助30
7秒前
哈基米发布了新的文献求助30
8秒前
勤劳白翠发布了新的文献求助30
9秒前
啊哈完成签到,获得积分10
9秒前
guoyanwu发布了新的文献求助10
9秒前
七七关注了科研通微信公众号
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188785
求助须知:如何正确求助?哪些是违规求助? 9576421
关于积分的说明 21847553
捐赠科研通 7786814
什么是DOI,文献DOI怎么找? 3435417
关于科研通互助平台的介绍 2559647
邀请新用户注册赠送积分活动 2482366